TCTR20220225004招募中4 期
The evaluation of ocular surface changes after switching to preservative-free tafluprost 0.0015%/ timolol 0.5% fixed combination
Department of Ophthalmology, Faculty of Medicine, Chiang Mai University0 个研究点目标入组 10 人开始时间: 2022年2月25日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 99 Years（—）
- 性别
- All
入选标准
- •1. Patients with established glaucoma or ocular hypertension at Chiang Mai University Hospital
- •2. Age 18 years or older
- •3. Different types of unilateral or bilateral glaucoma (primary open angle glaucoma, normal tension glaucoma, primary angle closure glaucoma, pseudoexfoliation glaucoma, and other glaucomas) or ocular hypertension
- •4. Have prior use of combination therapy of preserved timolol and preserved prostaglandin analogue (other than tafluprost) such as Two topical anti-glaucoma medications: One of them is preservative-containing prostaglandin (latanoprost, travoprost, or bimatoprost) monotherapy. The other medication is preservative-containing timolol 0.5% OR Preservative-containing fixed dose combination of prostaglandin and timolol 0.5%
- •5. Intraocular pressure not exceeding 22 mmHg at baseline visit
- •6. Regular use of anti-glaucoma medications as listed in the inclusion criteria (4) for not more than 3 months
- •7. No other topical medications applied with exception of anti-glaucoma medications and artificial tears
- •8. With or without previous intraocular/glaucoma surgery
- •9. Patients who have ocular surface disease due to the usage of preservative-containing anti-glaucoma medications. (At least one eye must have a score above 1 on the NEI scale)
- •10. If both eyes of a patient are eligible for enrollment, the eye with more ocular surface disease will be chosen for study
排除标准
- •1. Life threatening or debilitating disease
- •2. Inability to follow instructions as scheduled
- •3. Patients with pulmonary disease (asthma, chronic obstructive pulmonary disease), heart disease (arrhythmia, heart block) which is contraindication for timolol 0.5% use.
- •4. Patients with known history of timolol and/or prostaglandins analogs allergy
研究者
相似试验
尚未招募
Unknown
Visual disturbances of patients following operatioCTRI/2023/03/050562GCS medical college and hospital
已完成
不适用
Changes in the ocular surface parameters after cataract surgery in patients with type 2 diabetesKCT0006960Ewha Womans University Medical Center63
已完成
不适用
A study to analyse whether the type of glaucoma and combination of drugs affect the periocular changes.CTRI/2018/04/012949Giridhar Eye Institute32
进行中（未招募）
不适用
An Evaluation of the Ocular Surface Health in Subjects Using DUOTRAV APS Ophthalmic Solution Versus XALACOM Ophthalmic Solution - DuoTrav APS versus XALACOM in OSDIglaucoma/dry eyeMedDRA version: 9.1Level: LLTClassification code 10030348MedDRA version: 9.1Level: HLGTClassification code 10018307MedDRA version: 9.1Level: PTClassification code 10030043MedDRA version: 9.1Level: LLTClassification code 10013774EUCTR2009-010604-29-ITAlcon Research Ltd700
进行中（未招募）
不适用
An Evaluation of the Ocular Surface Health in Subjects Using Travoprost APS Eye Drops Solution Versus XALATAN Eye Drops Solution - Travoprost APS versus XALATAN in OSDIEUCTR2009-010606-10-HUAlcon Research, Ltd.700